-Late-breaking abstract to be presented on
November 3rd at
11:30 am PT highlighting pre-clinical
data with Moderna
-Two additional pre-clinical data abstracts
highlighting next-generation enhancements to Carisma's cell therapy
platform to be shared
PHILADELPHIA, Oct. 25,
2023 /PRNewswire/ -- Carisma Therapeutics Inc.
(Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative immunotherapies, today announced that new pre-clinical
data leveraging an mRNA platform to develop in-vivo
chimeric antigen receptor macrophage ("CAR-M") will be
presented as a late-breaking abstract (#LBA1514) at the upcoming
Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting held
from Wednesday, November 1, to
Sunday, November 5, 2023, in
San Diego, California. Two posters
highlighting next-generation enhancements to Carisma's CAR-M
platform, including a custom intronic shRNA approach and data on
Engineered Microenvironment Converters (EM-C), will also be
presented. Additionally, Carisma will share a trial-in-progress
poster overviewing its Phase 1 first-in-human (FIH) study design of
its lead program, CT-0508, sharing objectives and eligibility
criteria.
Carisma will participate in the virtual SITC 2023 Annual Meeting
Press Conference on Wednesday, November 1,
2023, from 12:00–1:30 pm PT.
"We are excited to present this pre-clinical data from our
collaboration with Moderna for the first time," said Steven Kelly, President and Chief Executive
Officer of Carisma. "Over the past year, we have leveraged the
expertise of both companies to pioneer the development of
in-vivo mRNA/LNP-based cell therapy. The study is exploring
the potential for an off-the-shelf treatment approach to enhance
therapeutic benefit for patients living with cancer."
Oral & Poster Presentations:
- In vivo CAR-M: Redirecting
endogenous myeloid cells with mRNA for cancer immunotherapy
- Primary Author: Bindu Varghese, PhD
- Presentation Type/#: Oral – 1514
- Session Date/Time (PT): Friday, November
3, 2023, 11:30 am, Session
104: Late Breaking Abstract Session
- CAR-Macrophages with custom intronic shRNA exhibit
enhanced efficacy against solid tumors
- Primary Author: Chris Sloas, PhD
- Presentation Type/#: Poster – 307
- Session Date/Time: Friday, November 3,
2023, 9:00 am – 7:00 pm
- Engineered Microenvironment Converters (EM-C): Macrophages
expressing synthetic cytokine receptors reverse immunosuppressive
signals in solid tumors
- Primary Author: Chris Sloas, PhD
- Presentation Type/#: Poster – 389
- Session Date/Time: Friday, November 3,
2023, 9:00 am – 7:00 pm
- A Phase 1, First in Human (FIH) study of autologous
macrophages engineered to express an anti-HER2 chimeric antigen
receptor (CAR) in participants (pts) with HER2 overexpressing solid
tumors
- Primary Author: Kim Reiss, MD
- Presentation Type/#: Poster – 635
- Session Date/Time: Friday, November 3,
2023, 9:00 am – 7:00 pm
Presentation and posters will be available in the Journal for
ImmunoTherapy of Cancer (JITC) supplement once published on
Tuesday, October 31, 2023, at
9:00 am ET.
About CT-0508
CT-0508 is a human epidermal growth factor receptor 2 (HER2)
targeted chimeric antigen receptor macrophage (CAR-M). It is being
evaluated in a landmark Phase 1 multi-center clinical trial that
focuses on patients with recurrent or metastatic
HER2-overexpressing solid tumors whose cancers do not have approved
HER2-targeted therapies or who do not respond to treatment. Carisma
is selecting participants who have tumors of any anatomical origin,
but with the commonality of overexpressing the HER2 receptor on the
cell surface, which is the target for our CAR-M. The Phase 1
clinical trial marks the first time that engineered macrophages are
being studied in humans. The trial continues to enroll patients at
seven clinical sites in the U.S., including (i) Penn Medicine's
Abramson Cancer Center, (ii) the University of
North Carolina Lineberger Comprehensive Cancer Center, (iii)
the City of Hope National Medical Center, (iv) the MD Anderson
Cancer Center, (v) the Sarah Cannon Cancer Research Institute, (vi)
Oregon Health & Science University and (vii) Fred Hutchinson
Cancer Center.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
About Moderna
In over 10 years since its inception, Moderna has transformed
from a research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across seven modalities, a
broad intellectual property portfolio and integrated manufacturing
facilities that allow for rapid clinical and commercial production
at scale. Moderna maintains alliances with a broad range of
domestic and overseas government and commercial collaborators,
which has allowed for the pursuit of both groundbreaking science
and rapid scaling of manufacturing. Most recently, Moderna's
capabilities have come together to allow the authorized use and
approval of one of the earliest and most effective vaccines against
the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past eight years. To
learn more, visit www.modernatx.com.
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Carisma's business,
strategy, future operations, cash runway, the advancement of
Carisma's product candidates and product pipeline, and clinical
development of Carisma's product candidates, including expectations
regarding timing of initiation and results of pre-clinical and
clinical trials. The words "anticipate," "believe," "contemplate,"
"continue," "could," "estimate," "expect," "goals," "intend,"
"may," "might," "outlook," "plan," "project," "potential,"
"predict," "target," "possible," "will," "would," "could,"
"should," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. For a discussion of these risks
and uncertainties, and other important factors, any of which could
cause Carisma's actual results to differ from those contained in
the forward-looking statements, see the "Risk Factors" set forth in
the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August
10, 2023, as well as discussions of potential risks,
uncertainties, and other important factors in Carisma's other
recent filings with the Securities and Exchange Commission. Any
forward-looking statements that are made in this press release
speak as of the date of this press release. Carisma undertakes no
obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Media Inquiries:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
Investor:
investors@carismatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-to-present-first-results-from-in-vivo-car-m-collaboration-with-moderna-at-sitc-2023-301967348.html
SOURCE Carisma Therapeutics Inc.